Activaero – novel solutions for severe respiratory diseases

We significantly improve the treatment of severe respiratory diseases and notably increase the quality of life for patients by developing cutting-edge solutions in the field of aerosolized therapies. The unique combination of efficacious, though underutilized, drugs with our unparalleled FAVORITE approach is fuelling a promising pipeline of highly effective, safer and significantly more cost-efficient pulmonary therapies. Activaero has a proven track-record in clinical development and partnering with leading pharma and biotech companies. Our lead product FAVOLIR® has shown outstanding clinical benefit in a pivotal clinical trial and will soon be filed for market approval in Europe.


News